Sökning: WFRF:(Verheugt Freek W A)
> (2015-2019) >
Oral anticoagulants...
-
De Caterina, RaffaeleUniv G DAnnunzio, Chieti, Italy.;Fdn Toscana G Monasterio, Pisa, Italy.
(författare)
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-300322
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300322URI
-
https://doi.org/10.1160/TH15-09-0703DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Until recently, vitamin K antagonists (VKAs) were the only available oral anticoagulants evaluated for long-term treatment of patients with coronary heart disease (CHD), particularly after an acute coronary syndrome (ACS). Despite efficacy in this setting, VKAs are rarely used because they are cumbersome to administer. Instead, the more readily manageable antiplatelet agents are the mainstay of prevention in ACS patients. This situation has the potential to change with the introduction of non-VKA oral anticoagulants (NOACs), which are easier to administer than VKAs because they can be given in fixed doses without routine coagulation monitoring. The NOACs include dabigatran, which inhibits thrombin, and apixaban, rivaroxaban and edoxaban, which inhibit factor Xa. Apixaban and rivaroxaban were evaluated in phase III trials for prevention of recurrent ischaemia in ACS patients, most of whom were also receiving dual antiplatelet therapy with aspirin and clopidogrel. Although at the doses tested rivaroxaban was effective and apixaban was not, both agents increased major bleeding. The role for the NOACs in ACS management, although promising, is therefore complicated, because it is uncertain how they compare with newer antiplatelet agents, such as prasugrel, ticagrelor or vorapaxar, and because their safety in combination with these other drugs is unknown. Ongoing studies are also now evaluating the use of NOACs in non-valvular atrial fibrillation patients, where their role is established, with coexistent ACS or coronary stenting. Focusing on CHD, we review the results of clinical trials with the NOACs and provide a perspective on their future incorporation into clinical practice.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Husted, SteenUniv Aarhus, Aarhus, Denmark.
(författare)
-
Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)larswall
(författare)
-
Andreotti, FelicitaUniv Cattolica Sacro Cuore, I-00168 Rome, Italy.
(författare)
-
Arnesen, HaraldOslo Univ Hosp Ulleval, Oslo, Norway.;Univ Oslo, Oslo, Norway.
(författare)
-
Bachmann, FedorUniv Lausanne, Lausanne, Switzerland.
(författare)
-
Baigent, ColinUniv Oxford, Oxford, England.
(författare)
-
Collet, Jean-PhilippeGrp Hosp Pitie Salpetriere, INSERM, UMRS ICAN 1166, F-75634 Paris, France.
(författare)
-
Halvorsen, SigrunOslo Univ Hosp Ulleval, Oslo, Norway.;Univ Oslo, Oslo, Norway.
(författare)
-
Huber, KurtWilhelminenhosp, Vienna, Austria.
(författare)
-
Jespersen, JorgenUniv Southern Denmark, Esbjerg, Denmark.
(författare)
-
Kristensen, Steen DalbyAarhus Univ Hosp, DK-8000 Aarhus, Denmark.
(författare)
-
Lip, Gregory Y. H.Univ Birmingham, City Hosp, Inst Cardiovasc Sci, Birmingham, W Midlands, England.
(författare)
-
Morais, JoaoHosp Santo Andre, Leiria, Portugal.
(författare)
-
Rasmussen, Lars HvilstedAalborg Univ, Aalborg, Denmark.
(författare)
-
Ricci, FabrizioUniv G DAnnunzio, Chieti, Italy.;Fdn Toscana G Monasterio, Pisa, Italy.
(författare)
-
Sibbing, DirkUniv Munich, Klinikum Univ Munchen, Med Klin & Poliklin 1, Munich, Germany.;DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany.
(författare)
-
Siegbahn, AgnetaUppsala universitet,Koagulation och inflammationsvetenskap(Swepub:uu)agsie424
(författare)
-
Storey, Robert F.Univ Sheffield, Sheffield, S Yorkshire, England.
(författare)
-
ten Berg, JurrienSt Antonius Hosp, Nieuwegein, Netherlands.
(författare)
-
Verheugt, Freek W. A.Onze Lieve Vrouw Hosp, Amsterdam, Netherlands.
(författare)
-
Weitz, Jeffrey I.McMaster Univ, Hamilton, ON, Canada.;Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada.
(författare)
-
Univ G DAnnunzio, Chieti, Italy.;Fdn Toscana G Monasterio, Pisa, Italy.Univ Aarhus, Aarhus, Denmark.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Thrombosis and Haemostasis115:4, s. 685-7110340-62452567-689X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
De Caterina, Raf ...
-
Husted, Steen
-
Wallentin, Lars
-
Andreotti, Felic ...
-
Arnesen, Harald
-
Bachmann, Fedor
-
visa fler...
-
Baigent, Colin
-
Collet, Jean-Phi ...
-
Halvorsen, Sigru ...
-
Huber, Kurt
-
Jespersen, Jorge ...
-
Kristensen, Stee ...
-
Lip, Gregory Y. ...
-
Morais, Joao
-
Rasmussen, Lars ...
-
Ricci, Fabrizio
-
Sibbing, Dirk
-
Siegbahn, Agneta
-
Storey, Robert F ...
-
ten Berg, Jurrie ...
-
Verheugt, Freek ...
-
Weitz, Jeffrey I ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Thrombosis and H ...
- Av lärosätet
-
Uppsala universitet